Cell Therapy for Cardiac Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (15 May 2025) | Viewed by 6125
Special Issue Editors
Interests: cardiovascular physiology; cardiomyocytes; hiPSC-derived cardiomyocytes; patch clamp; GPCR signaling
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality globally, demanding innovative therapeutic strategies beyond traditional pharmacological interventions. Cell-based therapies, particularly those utilizing human-derived stem cells, offer a promising avenue for personalized medicine approaches to cardiac repair and regeneration. This Special Issue focuses on the translational potential of various stem cell types in addressing the unmet clinical needs in cardiac disease. We welcome contributions exploring the entire spectrum of cell therapy research, from the fundamental biology of stem cell differentiation and characterization to preclinical and clinical applications.
This includes, but is not limited to, the following:
- Stem cell sources: the investigation of diverse stem cell sources, including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and cardiac progenitor cells (CPCs), and their suitability for cardiac repair.
- Differentiation and characterization: studies focusing on optimizing differentiation protocols to generate functional cardiomyocytes, endothelial cells, and other cardiac cell types, as well as a comprehensive characterization of their phenotype and functionality.
- Delivery methods: research exploring efficient and safe delivery strategies for stem cells, including intramyocardial injection, intravenous infusion, and biomaterial-based approaches.
- Preclinical studies: in vitro and in vivo studies evaluating the efficacy and safety of stem cell therapies in relevant animal models of cardiac disease.
- Clinical trials: reports on ongoing or completed clinical trials examining the therapeutic potential of stem cell therapies for various cardiac conditions, such as myocardial infarction, heart failure, and congenital heart defects.
- Drug screening and development: exploration of the use of stem cell-derived models for drug screening, toxicity assessment, and the identification of novel therapeutic targets.
- Challenges and future directions: discussions on the current limitations of stem cell therapies and potential strategies to overcome them, as well as future directions for the field.
We encourage submissions of original research articles, reviews, and perspectives that advance our understanding and application of cell-based therapies for cardiac disease.
Dr. Daniela Malan
Dr. Giulia Querio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell therapy
- cardiac disease
- stem cells
- induced pluripotent stem cells (iPSCs)
- embryonic stem cells (ESCs)
- mesenchymal stem cells (MSCs)
- cardiac progenitor cells (CPCs)
- myocardial infarction
- heart failure
- regenerative medicine
- cardiovascular regeneration
- drug screening
- personalized medicine
- cell differentiation
- cell delivery
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
